Pharmacotherapy in post-traumatic stress disorder: Evidence from randomized controlled trials

Current Opinion in Investigational Drugs

Volumn 10, Issue 1, 2009, Pages 35-45

  Sullivan, G M ^a   Neria, Y ^a  

^a Department of Psychiatry ^*  (United States)

Author keywords

Adrenergic antagonist; Anticonvulsant; Antipsychotic; Pharmacotherapy; Post traumatic stress disorder; Randomized controlled trial; SSRI; Treatment

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; CITALOPRAM; CYCLOSERINE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; LAMOTRIGINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TIAGABINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; POSTTRAUMATIC STRESS DISORDER; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ADRENERGIC ANTAGONISTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; MONOAMINE OXIDASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME;

EID: 58449116017     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB: Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry (1995) 52(12):1048-1060.
2. Creamer M, Burgess P, McFarlane AC: Post-traumatic stress disorder: Findings from the Australian National Survey of Mental Health and Well-being. Psychol Med (2001) 31(7):1237-1247.
3. Sareen J, Houlahan T, Cox BJ, Asmundson GJ: Anxiety disorders associated with suicidal ideation and suicide attempts in the National Comorbidity Survey. J Nerv Ment Dis (2005) 193(7):450-454.
4. Druss BG, Hwang I, Petukhova M, Sampson NA, Wang PS, Kessler RC: Impairment in role functioning in mental and chronic medical disorders in the United States: Results from the National Comorbidity Survey Replication. Mol Psychiatry (2008):doi:10.1038/mp.2008.13.
5. Brunello N, Davidson JR, Deahl M, Kessler RC, Mendlewicz J, Racagni G, Shalev AY, Zohar J: Posttraumatic stress disorder: Diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. Neuropsychobiology (2001) 43(3):150-162. • Despite being published in 2001, this is a comprehensive review of PTSD epidemiology, neurobiology and treatment that remains relevant.
6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 4th edition. American Psychiatric Publishing Inc, Arlington, VA, USA (2000).
7. Neria Y, Gross R, Olfson M, Gameroff MJ, Wickramaratne P, Das A, Pilowsky D, Feder A, Blanco C, Marshall RD, Lantigua R et al: Posttraumatic stress disorder in primary care one year after the 9/11 attacks. Gen Hosp Psychiatry (2006) 28(3):213-222. • This paper described a systematic sampling of an adult primary care population in New York City with high rates of exposure to trauma from the September 11th (9/11) terror attacks. Factors associated with higher rates of PTSD symptomology included ethnicity, immigrant status, marital status, family psychiatric history and presence of pre-9/11 trauma.
8. Stein MB, Walker JR, Hazen AL, Forde DR: Full and partial posttraumatic stress disorder: Findings from a community survey. Am J Psychiatry (1997) 154(8):1114-1119.
9. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM: The development of a Clinician-Administered PTSD Scale. J Trauma Stress (1995) 8(1):75-90.
10. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Klauminzer G, Charney DS, Keane T: A clinician rating scale for assessing current and lifetime PTSD: The CAPS-1. Behav Ther (1990) 13:187-188.
11. National Institute of Mental Health: CGI: Clinical Global Impressions. In: Manual for the ECDEU Assessment Battery Volume 2. Guy W, Bonato RR (Eds), National Institute of Mental Health, Bethesda, MD, USA (1970):12.1-12.6.
12. Horowitz M, Wilner N, Alvarez W: Impact of event scale: A measure of subjective stress. Psychosom Med (1979) 41(3):209-218.
13. Davidson JR, Book SW, Colket JT, Tupler LA, Roth S, David D, Hertzberg M, Mellman T, Beckham JC, Smith RD, Davison RM et al: Assessment of a new self-rating scale for post-traumatic stress disorder. Psychol Med (1997) 27(1):153-160.
14. Committee on Treatment of Posttraumatic Stress Disorder, Institute of Medicine: Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence. The National Academies Press, Washington DC, USA (2008). •• This is the Institute of Medicine committee report on the treatment of PTSD, including a systematic analysis of pharmacotherapeutic trials in chapter 3, with tables listing populations studied, outcome measures, handling of dropouts, changes in outcome measure scores, statistical significance for changes in outcome measures and principal limitations of the clinical trials.
15. Post-traumatic stress disorder (PTSD): The management of PTSD in adults and children in primary and secondary care. National Institute for Clinical Excellence, London, UK (2005). http://www.nice.org.uk/nicemedia/pdf/ CG026NICEguideline.pdf •• PTSD treatment guidelines commissioned by the UK's National Institute for Clinical Excellence recommend that pharmacotherapy is not used as routine first-line treatment for adults, with trauma-focused psychological therapy as the preferred treatment option. This is based on an a priori requirement of a standardized mean difference ≤ -0.5 as an indicator of a clinically meaningful difference between drug and placebo.
16. Stein DJ, Ipser JC, Seedat S: Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev (2006) 1:CD002795. •• This systematic review and meta-analysis of controlled, randomized pharmacotherapeutic trials for PTSD includes 35 short-term (≤ 14 weeks) trials. Objectives were to estimate the effects of drug treatment in reducing PTSD symptoms, determine the more efficacious drug classes, and identify clinical and methodological factors predicting treatment response.
17. Bisson JI, Ehlers A, Matthews R, Pilling S, Richards D, Turner S: Psychological treatments for chronic post-traumatic stress disorder. Systematic review and meta-analysis. Br J Psychiatry (2007) 190:97-104. •• A meta-analysis of 38 RCTs of psychotherapies for the treatment of PTSD. Trauma-focused cognitive-behavioral therapy, and eye-movement desensitization and reprocessing were observed to be superior to other psychotherapeutic strategies.
18. American Psychiatric Association: Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. American Psychiatric Association, Arlington, VA, USA (2004).
19. Haglund ME, Nestadt PS, Cooper NS, Southwick SM, Charney DS: Psychobiological mechanisms of resilience: Relevance to prevention and treatment of stress-related psychopathology. Dev Psychopathol (2007) 19(3):889-920.
20. Yehuda R, LeDoux J: Response variation following trauma: A translational neuroscience approach to understanding PTSD. Neuron (2007) 56(1):19-32. • This is a thorough review of the neurobiology of PTSD and the roles of preclinical models for improving the understanding of PTSD development as it contrasts with resilience in the face of trauma. Treatment interventions derived from preclinical models, such as those involving fear memory consolidation and extinction, are discussed.
21. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol (2005) 19(6):567-596.
22. The post-traumatic stress disorder (PTSD) algorithm. Project IPA, Princeton, NJ, USA (2005). http://www.ipap.org/algorithms.php
23. Management of post-traumatic stress. Group VDCPGW, Washington DC, USA (2003). http://www.oqp.med.va.gov/cpg/PTSD/PTSD-Base.htm
24. Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW: Adjunctive risperidone treatment in post-traumatic stress disorder: A preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol (2003) 18(1):1-8.
25. Davis LL, Davidson JR, Ward LC, Bartolucci A, Bowden CL, Petty F: Divalproex in the treatment of posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol (2008) 28(1):84-88.
26. Monnelly EP, Ciraulo DA, Knapp C, Keane T: Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol (2003) 23(2):193-196.
27. Hertzberg MA, Moore SD, Feldman ME, Beckham JC: A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. J Clin Psychopharmacol (2001) 21(1):94-98.
28. Brady KT, Sonne S, Anton RF, Randall CL, Back SE, Simpson K: Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res (2005) 29(3):395-401.
29. Pitman RK, Sanders KM, Zusman RM, Healy AR, Cheema F, Lasko NB, Cahill L, Orr SP: Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry (2002) 51(2):189-192. • This small pilot RCT for PTSD prevention with propranolol treatment (initiated within 6 h of the index trauma) did not demonstrate a significant effect of propranolol on PTSD development. However, propranolol did appear to have an effect on the reduction of physiological activation upon challenge with trauma-specific mental imagery.
30. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: A randomized controlled trial. J Am Med Assoc (2000) 283(14):1837-1844.
31. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM: Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry (2001) 58(5):485-492.
32. Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM: Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry (2007) 68(5):711-720.
33. Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR: Lack of efficacy for fluoxetine in PTSD: A placebo controlled trial in combat veterans. Ann Clin Psychiatry (2000) 12(2):101-105.
34. Marshall RD, Beebe KL, Oldham M, Zaninelli R: Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. Am J Psychiatry (2001) 158(12):1982-1988.
35. Marshall RD, Lewis-Fernandez R, Blanco C, Simpson HB, Lin SH, Vermes D, Garcia W, Schneier F, Neria Y, Sanchez-Lacay A, Liebowitz MR: A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety (2007) 24(2):77-84.
36. Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC: Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry (2002) 63(3):199-206.
37. Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD: Paroxetine in the treatment of chronic posttraumatic stress disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry (2001) 62(11):860-868.
38. van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G: Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry (1994) 55(12):517-522.
39. van der Kolk BA, Spinazzola J, Blaustein ME, Hopper JW, Hopper EK, Korn DL, Simpson WB: A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: Treatment effects and long-term maintenance. J Clin Psychiatry (2007) 68(1):37-46.
40. Zohar J, Amital D, Miodownik C, Kotler M, Bleich A, Lane RM, Austin C: Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol (2002) 22(2):190-195.
41. Tucker P, Potter-Kimball R, Wyatt DB, Parker DE, Burgin C, Jones DE, Masters BK: Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Psychopharmacol Bull (2003) 37(3):135-149.
42. Davidson J, Pearlstein T, Londborg P, Brady KT, Rothbaum B, Bell J, Maddock R, Hegel MT, Farfel G: Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: Results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry (2001) 158(12):1974- 1981.
43. Davidson JR, Connor KM, Hertzberg MA, Weisler RH, Wilson WH, Payne VM: Maintenance therapy with fluoxetine in posttraumatic stress disorder: A placebo-controlled discontinuation study. J Clin Psychopharmacol (2005) 25(2):166-169.
44. Londborg PD, Hegel MT, Goldstein S, Goldstein D, Himmelhoch JM, Maddock R, Patterson WM, Rausch J, Farfel GM: Sertraline treatment of posttraumatic stress disorder: Results of 24 weeks of open-label continuation treatment. J Clin Psychiatry (2001) 62(5):325-331.
45. Martenyi F, Brown EB, Zhang H, Koke SC, Prakash A: Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry (2002) 181:315-320.
46. Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Pedersen R, Musgnung J: Treatment of posttraumatic stress disorder with venlafaxine extended release: A 6-month randomized controlled trial. Arch Gen Psychiatry (2006) 63(10):1158-1165. • This is an example of a large, multicenter trial in which efficacy was demonstrated. Effect sizes for selected outcome measures are available, and results are compared with outcomes from other large pharmacotherapy RCTs for the treatment of PTSD.
47. Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ: Venlafaxine extended release in posttraumatic stress disorder: A sertraline- and placebo-controlled study. J Clin Psychopharmacol (2006) 26(3):259-267.
48. Davis LL, Jewell ME, Ambrose S, Farley J, English B, Bartolucci A, Petty F: A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: A preliminary study. J Clin Psychopharmacol (2004) 24(3):291-297.
49. Stewart DE: Hepatic adverse reactions associated with nefazodone. Can J Psychiatry (2002) 47(4):375-377.
50. Davidson JR, Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S, van Meter S: Mirtazapine vs. placebo in posttraumatic stress disorder: A pilot trial. Biol Psychiatry (2003) 53(2):188-191.
51. Becker ME, Hertzberg MA, Moore SD, Dennis MF, Bukenya DS, Beckham JC: A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol (2007) 27(2):193-197.
52. Falcon S, Ryan C, Chamberlain K, Curtis G: Tricyclics: Possible treatment for posttraumatic stress disorder. J Clin Psychiatry (1985) 46(9):385-388.
53. Hogben GL, Cornfield RB: Treatment of traumatic war neurosis with phenelzine. Arch Gen Psychiatry (1981) 38(4):440-445.
54. Shestatzky M, Greenberg D, Lerer B: A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res (1988) 24(2):149-155.
55. Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL Jr: Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis (1991) 179(6):366-370.
56. Davidson J, Kudler H, Smith R, Mahorney SL, Lipper S, Hammett E, Saunders WB, Cavenar JO Jr: Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry (1990) 47(3):259-266. •• This paper includes a review of the PTSD pharmacotherapy literature from the 1980s and a systematic discussion of numerous methodological problems with the clinical trials conducted during that decade.
57. Reist C, Kauffmann CD, Haier RJ, Sangdahl C, DeMet EM, Chicz-DeMet A, Nelson JN: A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry (1989) 146(4):513-516.
58. Baker DG, Diamond BI, Gillette G, Hamner M, Katzelnick D, Keller T, Mellman TA, Pontius E, Rosenthal M, Tucker P, vander Kolk BA, Katz R: A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology (1995) 122(4):386-389.
59. Katz RJ, Lott MH, Arbus P, Crocq L, Herlobsen P, Lingjaerde O, Lopez G, Loughrey GC, MacFarlane DJ, McIvor R, Mehlum L et al: Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety (1994) 1(4):169-174.
60. Connor KM, Hidalgo RB, Crockett B, Malik M, Katz RJ, Davidson JR: Predictors of treatment response in patients with posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry (2001) 25(2):337-345.
61. Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM, Davidson JR: A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry (1999) 45(9):1226-1229.
62. Tucker P, Trautman RP, Wyatt DB, Thompson J, Wu SC, Capece JA, Rosenthal NR: Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry (2007) 68(2):201-206.
63. Lindley SE, Carlson EB, Hill K: A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol (2007) 27(6):677-681.
64. Davidson JR, Brady K, Mellman TA, Stein MB, Pollack MH: The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol (2007) 27(1):85-88.
65. Braun P, Greenberg D, Dasberg H, Lerer B: Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry (1990) 51(6):236-238.
66. Mellman TA, Bustamante V, David D, Fins AI: Hypnotic medication in the aftermath of trauma. J Clin Psychiatry (2002) 63(12):1183- 1184.
67. Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, Blanaru M, Cohen T: Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol (2002) 5(4):301-307.
68. Padala PR, Madison J, Monnahan M, Marcil W, Price P, Ramaswamy S, Din AU, Wilson DR, Petty F: Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol (2006) 21(5):275-280.
69. Butterfield MI, Becker ME, Connor KM, Sutherland S, Churchill LE, Davidson JR: Olanzapine in the treatment of post-traumatic stress disorder: A pilot study. Int Clin Psychopharmacol (2001) 16(4):197-203.
70. Stein MB, Kline NA, Matloff JL: Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. Am J Psychiatry (2002) 159(10):1777-1779.
71. Rothbaum BO, Killeen TK, Davidson JR, Brady KT, Connor KM, Heekin MH: Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry (2008) 69(4):520-525.
72. Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS: Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry (2005) 57(5):474-479.
73. Reich DB, Winternitz S, Hennen J, Watts T, Stanculescu C: A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry (2004) 65(12):1601-1606.
74. Gold PE, Van Buskirk RB: Facilitation of time-dependent memory processes with posttrial epinephrine injections. Behav Biol (1975) 13(2):145-153.
75. McGaugh JL, Cahill L, Roozendaal B: Involvement of the amygdala in memory storage: Interaction with other brain systems. Proc Natl Acad Sci USA (1996) 93(24):13508-13514.
76. Stein MB, Kerridge C, Dimsdale JE, Hoyt DB: Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress (2007) 20(6):923-932.
77. Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE, Dobie DJ, Hoff D, Rein RJ, Straits-Tröster K, Thomas RG et al: Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: A placebo-controlled study. Am J Psychiatry (2003) 160(2):371-373.
78. Hilakivi I, Leppavuori A: Effects of methoxamine, and α-1 adrenoceptor agonist, and prazosin, an α-1 antagonist, on the stages of the sleep-waking cycle in the cat. Acta Physiol Scand (1984) 120(3):363-372.
79. Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, Shofer J, O'Connell J, Taylor F, Gross C, Rohde K et al: A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry (2007) 61(8):928-934. • In this RCT, prazosin demonstrated large effect sizes for reduction of trauma nightmares, improved sleep quality and improved global clinical status in a veteran patient group with chronic PTSD.
80. Taylor FB, Martin P, Thompson C, Williams J, Mellman TA, Gross C, Peskind ER, Raskind MA: Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: A placebo-controlled study. Biol Psychiatry (2008) 63(6):629-632.
81. Taylor FB, Lowe K, Thompson C, McFall MM, Peskind ER, Kanter ED, Allison N, Williams J, Martin P, Raskind MA: Daytime prazosin reduces psychological distress to trauma specific cues in civilian trauma posttraumatic stress disorder. Biol Psychiatry (2006) 59(7):577-581.
82. Neylan TC, Lenoci M, Samuelson KW, Metzler TJ, Henn-Haase C, Hierholzer RW, Lindley SE, Otte C, Schoenfeld FB, Yesavage JA, Marmar CR: No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry (2006) 163(12):2186-2188.
83. Stein MB, Yehuda R, Koverola C, Hanna C: Enhanced dexamethasone suppression of plasma cortisol in adult women traumatized by childhood sexual abuse. Biol Psychiatry (1997) 42(8):680-686.
84. Roozendaal B, Barsegyan A, Lee S: Adrenal stress hormones, amygdala activation, and memory for emotionally arousing experiences. Prog Brain Res (2008) 167:79-97.
85. Schelling G, Briegel J, Roozendaal B, Stoll C, Rothenhausler HB, Kapfhammer HP: The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol Psychiatry (2001) 50(12):978-985.
86. Jackson JC, Hart RP, Gordon SM, Hopkins RO, Girard TD, Ely EW: Post-traumatic stress disorder and post-traumatic stress symptoms following critical illness in medical intensive care unit patients: Assessing the magnitude of the problem. Crit Care (2007) 11(1):R27.